Compound Radar

Jazz Pharmaceuticals plc (JAZZ) Stock Analysis

Price $240.07
Market cap $15.58B
Next earnings Nov 4, 2026
Entry status Watch $195.80–$207.92

Last updated Sep 8, 2026

Health Check

Last analyzed Sep 7, 2026

66
66/100 Good Quality
  • Financial Health 50
  • Profitability 60
  • Business Quality 75
  • Balance Sheet 55
  • Cash Flow 80

Why this rating?

Health 66/100 — Good Quality

Strongest Cash Flow 80/100
Softest Financial Health 50/100
Watch

Worth tracking, but timing is mixed — not a clear setup yet.

Company overview

Jazz Pharmaceuticals plc (JAZZ) is a Biotechnology company in the Healthcare sector. Compound Radar rates Jazz Pharmaceuticals plc 66/100 (Good Quality) due to high business quality, strong revenue growth, and manageable leverage.

Investment profile

  • Quality High
  • Growth Strong
  • Balance Sheet Adequate
  • Valuation Attractive

Financial highlights

Valuation

  • P/E 16.43
  • Forward P/E 9.32
  • PEG 0.96
  • EV/Revenue 3.96

Profitability

  • Revenue Growth 15.5%
  • Gross Margin 91.4%
  • Operating Margin 26.9%
  • Net Margin 20.4%
  • ROE 22.1%

Financial strength

  • Cash $2.20B
  • Debt $4.41B
  • Net Cash $-2.21B
  • Free Cash Flow $1.15B
  • Current Ratio 1.78

Similar companies

Peers in Biotechnology, ranked by Financial Health.

Company Ticker
Price Current price

Latest quoted price for the name. Helps anchor the setup in today’s market level.

Health Entry

View all in Biotechnology →

FAQ

How Compound Radar scores and tracks Jazz Pharmaceuticals plc (JAZZ).

View Methodology & FAQ →